GTBP
Price
$2.06
Change
+$0.03 (+1.48%)
Updated
Jul 18 closing price
Capitalization
6.74M
TRAW
Price
$1.65
Change
+$0.05 (+3.12%)
Updated
Jul 21, 10:50 AM (EDT)
Capitalization
8.9M
Interact to see
Advertisement

GTBP vs TRAW

Header iconGTBP vs TRAW Comparison
Open Charts GTBP vs TRAWBanner chart's image
GT Biopharma
Price$2.06
Change+$0.03 (+1.48%)
Volume$38.9K
Capitalization6.74M
Traws Pharma
Price$1.65
Change+$0.05 (+3.12%)
Volume$1K
Capitalization8.9M
GTBP vs TRAW Comparison Chart in %
Loading...
GTBP
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
TRAW
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
GTBP vs. TRAW commentary
Jul 21, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is GTBP is a Hold and TRAW is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jul 21, 2025
Stock price -- (GTBP: $2.06 vs. TRAW: $1.60)
Brand notoriety: GTBP and TRAW are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: GTBP: 40% vs. TRAW: 3%
Market capitalization -- GTBP: $6.74M vs. TRAW: $8.9M
GTBP [@Biotechnology] is valued at $6.74M. TRAW’s [@Biotechnology] market capitalization is $8.9M. The market cap for tickers in the [@Biotechnology] industry ranges from $286.69B to $0. The average market capitalization across the [@Biotechnology] industry is $2.44B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

GTBP’s FA Score shows that 1 FA rating(s) are green whileTRAW’s FA Score has 1 green FA rating(s).

  • GTBP’s FA Score: 1 green, 4 red.
  • TRAW’s FA Score: 1 green, 4 red.
According to our system of comparison, both GTBP and TRAW are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

GTBP’s TA Score shows that 5 TA indicator(s) are bullish while TRAW’s TA Score has 5 bullish TA indicator(s).

  • GTBP’s TA Score: 5 bullish, 5 bearish.
  • TRAW’s TA Score: 5 bullish, 2 bearish.
According to our system of comparison, TRAW is a better buy in the short-term than GTBP.

Price Growth

GTBP (@Biotechnology) experienced а -7.62% price change this week, while TRAW (@Biotechnology) price change was +5.26% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +2.68%. For the same industry, the average monthly price growth was +13.07%, and the average quarterly price growth was +34.43%.

Industries' Descriptions

@Biotechnology (+2.68% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
TRAW($8.9M) has a higher market cap than GTBP($6.74M). GTBP YTD gains are higher at: -32.459 vs. TRAW (-81.982). GTBP has higher annual earnings (EBITDA): -12M vs. TRAW (-24.89M). TRAW has more cash in the bank: 15.9M vs. GTBP (2.37M). TRAW has higher revenues than GTBP: TRAW (227K) vs GTBP (0).
GTBPTRAWGTBP / TRAW
Capitalization6.74M8.9M76%
EBITDA-12M-24.89M48%
Gain YTD-32.459-81.98240%
P/E RatioN/AN/A-
Revenue0227K-
Total Cash2.37M15.9M15%
Total Debt0N/A-
FUNDAMENTALS RATINGS
GTBP vs TRAW: Fundamental Ratings
GTBP
TRAW
OUTLOOK RATING
1..100
508
VALUATION
overvalued / fair valued / undervalued
1..100
31
Undervalued
28
Undervalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
100100
PRICE GROWTH RATING
1..100
8993
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TRAW's Valuation (28) in the Biotechnology industry is in the same range as GTBP (31) in the null industry. This means that TRAW’s stock grew similarly to GTBP’s over the last 12 months.

TRAW's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as GTBP (100) in the null industry. This means that TRAW’s stock grew similarly to GTBP’s over the last 12 months.

TRAW's SMR Rating (100) in the Biotechnology industry is in the same range as GTBP (100) in the null industry. This means that TRAW’s stock grew similarly to GTBP’s over the last 12 months.

GTBP's Price Growth Rating (89) in the null industry is in the same range as TRAW (93) in the Biotechnology industry. This means that GTBP’s stock grew similarly to TRAW’s over the last 12 months.

GTBP's P/E Growth Rating (100) in the null industry is in the same range as TRAW (100) in the Biotechnology industry. This means that GTBP’s stock grew similarly to TRAW’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
GTBPTRAW
RSI
ODDS (%)
Bullish Trend 4 days ago
70%
N/A
Stochastic
ODDS (%)
Bullish Trend 4 days ago
82%
Bearish Trend 4 days ago
90%
Momentum
ODDS (%)
Bearish Trend 4 days ago
90%
Bullish Trend 4 days ago
82%
MACD
ODDS (%)
Bearish Trend 4 days ago
90%
Bullish Trend 4 days ago
70%
TrendWeek
ODDS (%)
Bearish Trend 4 days ago
90%
Bullish Trend 4 days ago
78%
TrendMonth
ODDS (%)
Bearish Trend 4 days ago
90%
Bearish Trend 4 days ago
90%
Advances
ODDS (%)
Bullish Trend 12 days ago
85%
Bullish Trend 5 days ago
75%
Declines
ODDS (%)
Bearish Trend 7 days ago
90%
N/A
BollingerBands
ODDS (%)
Bullish Trend 4 days ago
78%
Bearish Trend 4 days ago
90%
Aroon
ODDS (%)
Bullish Trend 4 days ago
83%
N/A
View a ticker or compare two or three
Interact to see
Advertisement
GTBP
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
TRAW
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
GFI24.220.24
+1.00%
Gold Fields Ltd
BSGM4.63-0.12
-2.53%
BioSig Technologies, Inc.
TCRX1.82-0.07
-3.70%
TScan Therapeutics
PHAT7.95-0.37
-4.45%
Phathom Pharmaceuticals
INTR6.91-0.39
-5.34%
Inter & Co

GTBP and

Correlation & Price change

A.I.dvisor indicates that over the last year, GTBP has been loosely correlated with BDRX. These tickers have moved in lockstep 39% of the time. This A.I.-generated data suggests there is some statistical probability that if GTBP jumps, then BDRX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To GTBP
1D Price
Change %
GTBP100%
+1.48%
BDRX - GTBP
39%
Loosely correlated
-0.87%
SLGL - GTBP
33%
Poorly correlated
-3.29%
TRAW - GTBP
31%
Poorly correlated
-1.23%
RAPT - GTBP
30%
Poorly correlated
+14.17%
PTCT - GTBP
28%
Poorly correlated
-1.85%
More

TRAW and

Correlation & Price change

A.I.dvisor indicates that over the last year, TRAW has been loosely correlated with SLGL. These tickers have moved in lockstep 47% of the time. This A.I.-generated data suggests there is some statistical probability that if TRAW jumps, then SLGL could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To TRAW
1D Price
Change %
TRAW100%
-1.23%
SLGL - TRAW
47%
Loosely correlated
-3.29%
RAPT - TRAW
45%
Loosely correlated
+14.17%
AVXL - TRAW
36%
Loosely correlated
-0.72%
GTBP - TRAW
31%
Poorly correlated
+1.48%
RXRX - TRAW
29%
Poorly correlated
+5.80%
More